Search

Artesunate

Artesunate is indicated for the initial treatment of severe malaria.[L14099] The World Health Organization recommends artesunate as first line treatment for severe malaria. … [A203948] Artesunate was granted FDA approval on 26 May 2020.[L14099]

Gemfibrozil

[A185777,L8525] Gemfibrozil is not a first line treatment and is prescribed to patients who have not responded adequately to weight loss, diet, exercise, and other medications. … Gemfibrozil is a fibric acid agent, similar to [clofibrate], used to treat Type IIb, IV, and V hyperlipidemias.

Ivosidenib

Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. … [L46287] It was fully approved by the EMA in May 2023.[L46596]

Racemethionine

A preparation of methionine that includes a mixture of D-methionine and L-methionine isomers.

Degarelix

Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008. … Reduction in testosterone is important in treating men with advanced prostate cancer.

Sulfamethoxazole

[L11830] It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps … Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria.

Mifamurtide

As a liposomal formulation, mifamurtide demonstrates an enhanced tumoricidal effect and improved safety profile [A31745]. Mifamurtide is marketed in Europe as Mepact for intravenous infusion. … While about 90% of patients with newly diagnosed osteosarcoma may achieve complete remission from first-line therapies, the prognosis is still poor for patients with non-metastatic osteosarcoma with lower

Migalastat

[L47036,L47057] As of August 2018, migalastat under Amicus Therapeutics' brand name Galafold is currently approved in Australia, Canada, European Union, Israel, Japan, South Korea, Switzerland, and … This enzyme is responsible for breaking down glycosphingolipid substrate that, when deficient in patients with Fabry disease, builds up in the blood vessels, the kidneys, the nerves, the heart, and other

Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)